Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 24fludarabine phosphate 22Filgrastim 15Gemcitabine 14fludarabine 13Rituximab 13Brentuximab Vedotin 13Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Bortezomib 10Mycophenolic Acid 9Melphalan 9Etoposide 9Busulfan 9Sirolimus 8Lenalidomide 8Azacitidine 8Nivolumab 7Dexamethasone 7pembrolizumab 6Radiotherapy 6Cytarabine 6Antilymphocyte Serum 6romidepsin 5aldesleukin 5Panobinostat 5Leucovorin 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hodgkin Disease × romiplostim × Clear all
NCT02046291 2021-06-08

Safety of Romiplostim (Nplate®) Following UCBT

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡